Fig. 1From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation typesInclusion and exclusion criteria of patient enrolment. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; TKIs, tyrosine kinase inhibitors; AEs, adverse events; E19del, exon 19 deletion; L858R, L858R point mutation; uncommon, uncommon mutationsBack to article page